Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Current Assets (2019 - 2025)

Bioadaptives' Current Assets history spans 7 years, with the latest figure at $108860.0 for Q3 2025.

  • For Q3 2025, Current Assets rose 134.65% year-over-year to $108860.0; the TTM value through Sep 2025 reached $108860.0, up 134.65%, while the annual FY2024 figure was $261885.0, 195.72% up from the prior year.
  • Current Assets for Q3 2025 was $108860.0 at Bioadaptives, down from $255515.0 in the prior quarter.
  • Across five years, Current Assets topped out at $261885.0 in Q4 2024 and bottomed at $8735.0 in Q2 2024.
  • The 5-year median for Current Assets is $61227.0 (2022), against an average of $84817.1.
  • The largest annual shift saw Current Assets plummeted 82.29% in 2023 before it skyrocketed 2825.19% in 2025.
  • A 5-year view of Current Assets shows it stood at $88876.0 in 2021, then crashed by 61.38% to $34324.0 in 2022, then skyrocketed by 158.0% to $88557.0 in 2023, then skyrocketed by 195.72% to $261885.0 in 2024, then tumbled by 58.43% to $108860.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Current Assets are $108860.0 (Q3 2025), $255515.0 (Q2 2025), and $110448.0 (Q1 2025).